zurück

Glycopyrronium (known active substance with new document protection (§16): severe primary axillary hyperhidrosis)

 

Subject:

  • Active Sustance: Glycopyrronium
  • Name: Axhidrox®
  • Therapeutic area: Axillary hyperhidrosis
  • Pharmaceutical company: Dr. August Wolff GmbH & Co. KG Arzneimittel

 

Time table:

  • Start: 01.08.2022
  • Publication of assessment: 01.11.2022
  • End of public hearing: 22.11.2022
  • Final decision by G-BA: middle of January 2023

 

Comparative therapy:

  • A formulation containing aluminium chloride (min. 15 %) or tap water iontophoresis